Cite
Bu DX, Singh R, Choi EE, et al. Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma. Oncotarget. 2018;9(40):25764-25780doi: 10.18632/oncotarget.25359.
Bu, D. X., Singh, R., Choi, E. E., Ruella, M., Nunez-Cruz, S., Mansfield, K. G., Bennett, P., Barton, N., Wu, Q., Zhang, J., Wang, Y., Wei, L., Cogan, S., Ezell, T., Joshi, S., Latimer, K. J., Granda, B., Tschantz, W. R., Young, R. M., Huet, H. A., Richardson, C. J., & Milone, M. C. (2018). Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma. Oncotarget, 9(40), 25764-25780. https://doi.org/10.18632/oncotarget.25359
Bu, De-Xiu, et al. "Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma." Oncotarget vol. 9,40 (2018): 25764-25780. doi: https://doi.org/10.18632/oncotarget.25359
Bu DX, Singh R, Choi EE, Ruella M, Nunez-Cruz S, Mansfield KG, Bennett P, Barton N, Wu Q, Zhang J, Wang Y, Wei L, Cogan S, Ezell T, Joshi S, Latimer KJ, Granda B, Tschantz WR, Young RM, Huet HA, Richardson CJ, Milone MC. Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma. Oncotarget. 2018 May 25;9(40):25764-25780. doi: 10.18632/oncotarget.25359. eCollection 2018 May 25. PMID: 29899820; PMCID: PMC5995247.
Copy
Download .nbib